Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-04-27 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
2022年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022年度募集资金存放与实际使用情况的专项报告" which translates to "2022 Annual Special Report on the Deposit and Actual Use of Raised Funds." It details the company's fundraising activities, the amount raised, usage of the funds, management of the funds, and compliance with regulatory requirements. It includes detailed financial figures about the raised capital, usage, and cash management, as well as auditor and sponsor opinions confirming compliance and proper use of funds. The document is 6632 characters long, which is substantial and contains detailed financial and operational data about fundraising and capital usage. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report publication, nor a full annual report or interim report. Therefore, the correct classification is CAP with high confidence.
2023-04-27 Chinese
中信证券股份有限公司关于海创药业股份有限公司2023年度关联交易预计的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an opinion on the expected related party transactions for the year 2023 by CITIC Securities as the sponsor for Haichuang Pharmaceutical Co., Ltd. It contains detailed information about the nature, amounts, and approval procedures of related party transactions expected in 2023. The document includes independent directors' opinions, board resolutions, and sponsor's verification opinions. It is a specialized report focusing on related party transactions and their compliance with regulatory requirements, rather than a general financial report or announcement. The document length is 3598 characters, which is relatively short but contains substantive content and detailed analysis, not just an announcement or certification. This fits best with the category of Audit Report / Information (AR), as it involves verification and audit-like review of related party transactions, their fairness, and compliance, but is not a full annual report or interim report. Therefore, the classification is AR with high confidence. FY 2023
2023-04-27 Chinese
2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, their identification, and rectification. The content is focused on internal control evaluation, which is typically part of audit-related documentation rather than a full annual report or earnings release. The document length is 4288 characters, which is relatively short but contains detailed internal control evaluation content, not just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations. It is not a full Annual Report (10-K), nor a simple announcement or certification (RNS). FY 2022
2023-04-27 Chinese
关于公司2023年度关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from a company regarding its expected related party transactions for the year 2023. It includes details about the nature of the transactions, the approval process by the board and audit committee, independent directors' opinions, and the sponsor's verification. The document explicitly states that the related party transactions do not require shareholder meeting approval and provides detailed financial estimates and explanations. The content focuses on disclosure of related party transactions and their governance, rather than presenting a full financial report or audit. The document length is 3580 characters, which is relatively short and typical for an announcement rather than a full report. This fits the profile of a Regulatory Filing (RNS) as it is a regulatory disclosure about related party transactions, not a full Annual Report, Audit Report, or Interim Report. It is not a report publication announcement since it contains substantive information, not just a notice of report availability.
2023-04-27 Chinese
独立董事关于公司第一届董事会第二十六次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on matters to be discussed at the company's 26th board meeting of the first board session. It includes opinions on the proposal to reappoint the 2023 financial and internal control audit firm and on the estimated related party transactions for 2023. The document is not a full audit report but rather an approval or endorsement related to audit and related party transaction proposals. It does not contain financial statements or detailed audit results. It is also not a management report or regulatory filing. The content aligns with board/management information regarding board meeting matters and approvals. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2023-04-27 Chinese
关于公司2023年度向金融机构申请授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company Hai Chuang Pharmaceutical Co., Ltd. regarding the application for credit facilities from financial institutions for the year 2023. It details the board's approval to authorize management to apply for a credit limit up to 600 million RMB, the types of credit facilities involved, and the authorization granted to the chairman or designated agents to handle the credit matters. There is no financial statement, earnings data, or detailed report content. The document is an update on financing activities, specifically about credit/loan applications and authorizations. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Confidence is high due to clear content about financing authorization.
2023-04-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.